Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London afternoon: Shares aim higher

Fri, 28th Aug 2009 14:27

London's blue chips have added to gains in afternoon trading ahead of what is expected to be a rosy start on Wall Street.US stocks are seen posting good gains after Intel hiked its third-quarter revenue outlook just before the open.Kazakhmys, Xstrata, Rio Tinto, Antofagasta, Randgold Resources, Anglo American and Vedanta Resources are all amongst the major risers.Lloyds is amongst the risers on rumours that it is considering alternatives to the government's toxic asset protection scheme (APS), which could include the sale of Scottish Widows or even a rights issue. The part-nationalised lender may also sell Clerical Medical, a provider of investment products and pensions.National Express dropped after it rejected the improved 450p per share offer from a consortium led by its main shareholder, saying that it undervalued the group and its prospects.Bus and rail operator Stagecoach said conditions remain challenging as it reported a 4.4% rise in like-for-like UK bus revenues and a 0.9% rise in UK rail revenues in the 12 weeks to July 26. Online gaming giant PartyGaming saw pre-tax profits rise at the half year stage, but revenues fell by 21% predominantly due to the strength of the dollar against the euro and sterling. Cost control measures and a refusal to slash prices helped Restaurant Group, the company behind the Frankie & Bennie's and Chiquito chains, to post a rise in profits for the first half of the year despite falling sales at its restaurants.Oil explorer Dana Petroleum reported a sharp drop in first half profits in what it called a very difficult macro economic environment. Profit before tax for the period was £21.9m from £133.1m last time. JKX Oil meanwhile saw lower oil prices crimp profits for the half-year but said its second half performance is expected to be in line with expectations.Oil explorer Heritage Oil reduced half year losses and said growth prospects never looked better, while fellow oil and gas firm Melrose Resources upgraded its full year production guidance but saw half-year results also hit by lower commodity prices.Independent News and Media, the Irish publisher of the UK's Independent newspaper, swung to a first-half net loss and said it expects full-year profits to be at the low end of guidance.Edinburgh based publisher Johnston Press said half year pre-tax losses swelled to £94m as revenues fell 25%. The group, which produces the Yorkshire Post and The Scotsman, said pre-tax loss swelled to £94.2m in the 26 Weeks to 30 June 2009 from a loss of £53.7m the year before. Revenue fell to £218.6m.Advertising firm Aegis saw profits slide in the first half of the year after the downturn in the sector proved more difficult than expected. Pre-tax profits for the period totalled £6.6m compared with £47.4m for the first half of 2008. Revenue climbed to £636.7m from £607.6m due to positive currency effects.Laundry and workwear firm Davis Service Group posted a slight fall in pre-tax profits in the first half of the year as it continued to experience tough trading in its main markets.Upmarket cooker maker Aga moved into the red in the half year to 30 June and expects Autumn sales to match levels seen the same time last year.Investment bank Evolution saw adjusted operating profit jump 102% in the half year ended 30 June to £9.1m as Investment Banking income rose 93% to £33.9m, mainly from more sustainable secondary equities and fixed income commissions.FTSE 100 - RisersKazakhmys (KAZ) 997.50p +6.46%Lloyds Banking Group (LLOY) 110.74p +5.77%Xstrata (XTA) 834.00p +5.30%Eurasian Natural Resources (ENRC) 870.00p +4.82%Randgold Resources (RRS) 3,642.00p +4.66%Lonmin (LMI) 1,476.00p +4.38%Wolseley (WOS) 1,463.00p +4.13%Antofagasta (ANTO) 770.00p +3.98%FTSE 100 - FallersSerco Group (SRP) 470.00p -2.67%Pennon Group (PNN) 461.50p -1.33%BG Group (BG.) 1,032.00p -0.86%Schroders NV (SDRC) 911.00p -0.82%United Utilities Group (UU.) 462.20p -0.75%National Grid (NG.) 600.00p -0.66%Cobham (COB) 202.80p -0.64%Schroders (SDR) 1,080.00p -0.64%
More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.